Champions Oncology, Inc. (CSBR) is a US-based leading technology-enabled company dedicated to personalizing the development and use of therapeutics for oncology. The firm started as Champions Biotechnology in 2007 and changed its name to Champions Oncology in 2011, reflecting its evolution as a leader in the burgeoning field of oncology personalized medicine. The company is publicly traded and listed on NASDAQ as CSBR.
Champions Oncoogy has revolutionized the way oncology is practiced by providing an end-to-end range of research and development solutions, thereby transforming the hope of patients battling cancer into success stories. With their head operations at Hackensack, NJ, they have satellite locations around the globe, including in the United Kingdom and Singapore.
The company’s key product, TumorGraft, is recognized due to its exceptional predictability. This technology involves the implantation of human tumor samples into immune-deficient mice, allowing personalized animal models that mirror the patient's unique cancer biology. This technique has proved transformative and innovative in efforts to enhance cancer therapy effectiveness, directing the development of personalized treatment plans and providing the tools to develop and trial novel cancer agents.
In addition to TumorGraft, Champions Oncology is also recognized for its mastery in pharmacology, therapeutic expertise, and bioinformatics, giving the company a competitive edge in the industry. Champions Oncology’s technologies in oncology research has been utilized by numerous pharmaceutical and biotech companies across the globe, including academic centers, and government research organizations.
Champions Oncology, Inc's primary revenue comes from research products and services offered to bio-pharma companies, academic institutions, and individual patients. Their unique approach and proven technology platforms have resulted in substantial contributions to the pharmaceutical space, streamlining the road to developing new treatments and personalizing medicine.
Overall, Champions Oncology, Inc. (CSBR) embodies a paradigm change in translational oncology research. Their pioneering approach and technology solutions have not just fast-tracked the development of new cancer therapies but have also facilitated a more effective way to manage and treat cancer. Their relentless work, combined with advanced science, makes them a true champion in oncological research and service provision.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Champions Oncology (NASDAQ: CSBR) reported its Q1 2027 earnings, with CEO Rob Brainin highlighting that the company is moving in the right direction after an investment year in fiscal 2026. Revenue reached $15.2 million, up from $14 million in Q1 fiscal '26, with a gross margin of 50% and adjusted EBITDA of approximately $700,000. The company saw strong performance in both its translational oncology services and data licensing businesses, with continued progress on its wholly-owned therapeutic subsidiary, Corellia.
Shares of Champions Oncology, Inc. (CSBR) slipped 1.8% despite the company reporting an 8.8% increase in Q1 fiscal 2027 revenues to $15.2 million and improved oncology services margin to 51%. The GAAP net loss narrowed, and adjusted EBITDA rose, driven by stronger conversion of pharmacology work and increased data licensing, though the company did not provide formal guidance. Management noted increased commercial activity and continued investment in sales and marketing, while strategically shifting focus from certain offerings.
Champions Oncology (CSBR) reported strong Q1 fiscal year 2027 earnings, with revenue growing 8.8% year over year to $15.2 million and adjusted EBITDA increasing significantly to $671,000. The company saw improved oncology services margins, reduced costs due to in-house radiolabeling, and notable growth in data licensing revenue. Management emphasized that strategic investments made in the previous fiscal year are now paying off, leading to increased profitability and continued discussions for external funding for its subsidiary, Corellia.